Can minimal residual disease (MRD) measurements aid your clinical decision-making?


Learn more about using MRD in practice from leading experts

As treatments for hematological malignancies become more effective, the need for more sensitive testing arises.
Listen to experts from across the globe presenting data and discussing the latest developments in MRD measurement.

The views and opinions expressed in these presentations specific to clinical judgements and decision making are those of the individual speaker.

Filter by:

Controversies in Multiple Myeloma (COMy) Online Meeting 2020

Dr. IIan ‘Lanny’ Kirsch, Dr. Bruno Paiva, Dr. Karthik Ramasamy

View the expert presentations and join in on the interactive case studies by selecting your choices to the poll questions.


Dr. Lanny Kirsch, Senior Vice President of Translational Medicine at Adaptive Biotechnologies, on the prognostic values of MRD in Multiple Myeloma (MM)

Dr. Bruno Paiva, University of Navarra, on the relevance of depth of response and sustained MRD negativity in Multiple Myeloma (MM)

Dr. Karthik Ramasamy, Consultant Hematologist at the Oxford University Hospitals NHS Foundation Trust, on managing Multiple Myeloma (MM) in real world practice: How can MRD inform treatment decisions?

Explore the use of clonoSEQ Assay B-Cell Reagent Set (Europe)

How it Works Clinical Data

The clonoSEQ Assay B-Cell Reagent Set is CE marked as an in vitro diagnostic (IVD) for assessing the MRD status and changes in disease burden during and after treatment in B-Cell malignancies in DNA extracted from blood and/or bone marrow samples.

Contact Us

Make an inquiry to learn more about our products.

Request information